Our present work demonstrates that a selective blockade of IL-6 trans-signaling with recombinant sgp130, in its native form without any modification, shows promising efficacy against HCC in the DEN-induced mouse model and also against xenograft human HCC in NOD/SCID mice. Here, IL6 is linked to hepatocellular carcinoma.